In 2015, a US court ruled that three companies (i.e. the litigants who had not previously settled out of court) that had licensed Mr. Nakamura's patents for production in the United States had infringed Dr. Moustakas's prior patent, and order them to pay licensing fees of not less than 13 million USD.